Department of Urology, Icahn School of Medicine at Mount Sinai , New York , New York.
Departments of Radiation Oncology and Pathology, University of Colorado Anschutz Medical Campus , Aurora , Colorado.
J Urol. 2019 Aug;202(2):264-271. doi: 10.1097/JU.0000000000000204. Epub 2019 Jul 8.
We sought to determine the minimum number of transperineal prostate mapping biopsies needed to optimize the prostate cancer detection rate.
A total of 436 men underwent transperineal prostate mapping biopsy at 2 institutions. Biopsy density was calculated as the ratio of the total number of specimens retrieved (mean 59.4) to prostate volume (mean 44.9 cc). Associations of biopsy density with prostate specific antigen, prostate specific antigen density, cancer diagnosis and the Gleason score were tested by ANOVA and the chi-square test. Regression analysis was done to determine factors associated with a positive transperineal prostate mapping biopsy and Gleason score 7 or higher cancer.
Transperineal prostate mapping biopsy was positive in 299 of 436 men (68.6%). The mean number of positive cores was 7.1 (range 1 to 41) and mean biopsy density was 1.46 (range 0.39 to 3.67). The mean number of cores in positive vs negative transperineal prostate mapping biopsies was 1.61 vs 1.14 (p <0.001). Biopsy density cut points of 0.5 or less, greater than 0.5 to 1.0, greater than 1.0 to 1.5 and greater than 1.5 were associated with positive biopsy in 25%, 37.4%, 70.7% and 84.9% of patients (p <0.001). Dichotomizing biopsy density to 1.5 or less vs greater than 1.5 resulted in a positive biopsy rate of 56.4% vs 84.9% (OR 1.5, 95% CI 1.3-1.7, p <0.001). More Gleason score 6 cancers were diagnosed with higher biopsy density (94 of 158 or 59.5% vs 62 of 141 or 44.9%, p = 0.007). However, the number of positive cores with Gleason score 6 was greater in men with higher biopsy density at 4.9 vs 3.6 (p = 0.036). Prostate specific antigen (p = 0.053) and biopsy density (p = 0.012) were significant on regression analysis for positive transperineal prostate mapping biopsy and Gleason score 7+ disease.
Biopsy density greater than 1.5 increases the diagnosis of prostate cancer by 1.5 times, detects higher volume Gleason score 6 disease and should be considered the optimal sampling approach when performing transperineal prostate mapping biopsy.
我们旨在确定经会阴前列腺图谱活检的最小次数,以优化前列腺癌的检出率。
在 2 家机构中,共有 436 名男性接受了经会阴前列腺图谱活检。活检密度的计算方法为总标本数(平均 59.4 个)与前列腺体积(平均 44.9cc)的比值。通过方差分析和卡方检验检测活检密度与前列腺特异性抗原、前列腺特异性抗原密度、癌症诊断和 Gleason 评分的相关性。进行回归分析以确定与经会阴前列腺图谱活检阳性和 Gleason 评分 7 或更高的癌症相关的因素。
436 名男性中有 299 名(68.6%)经会阴前列腺图谱活检阳性。平均阳性核心数为 7.1(范围 1 至 41),平均活检密度为 1.46(范围 0.39 至 3.67)。阳性与阴性经会阴前列腺图谱活检之间的核心数分别为 1.61 与 1.14(p <0.001)。活检密度切点为 0.5 或以下、大于 0.5 至 1.0、大于 1.0 至 1.5 和大于 1.5 时,与 25%、37.4%、70.7%和 84.9%的患者活检阳性相关(p <0.001)。将活检密度二分类为 1.5 或以下与大于 1.5 时,阳性活检率分别为 56.4%与 84.9%(OR 1.5,95%CI 1.3-1.7,p <0.001)。更高的活检密度与更多的 Gleason 评分 6 癌症诊断相关(158 例中有 94 例或 59.5%,141 例中有 62 例或 44.9%,p = 0.007)。然而,在更高活检密度的男性中,Gleason 评分 6 的阳性核心数更多,分别为 4.9 与 3.6(p = 0.036)。前列腺特异性抗原(p = 0.053)和活检密度(p = 0.012)在回归分析中与经会阴前列腺图谱活检阳性和 Gleason 评分 7+疾病相关。
活检密度大于 1.5 可使前列腺癌的诊断增加 1.5 倍,检测到更大体积的 Gleason 评分 6 疾病,在进行经会阴前列腺图谱活检时应考虑作为最佳采样方法。